E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs to treat genetically-defined subpopulations in neurodegenerative diseases.

Our focus on genetically defined subpopulations allows us to target therapies for patients where their disease is specifically driven by a genetic alteration. This approach provides greater confidence in our drug targets, focus our therapeutic approach and allows us to develop treatments for homogenous patient populations. Our programs aim to improve the lives of patients suffering from Alzheimer's Disease, Parkinson's Disease and Lysosomal Storage Disorders.